nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—CYP3A4—breast cancer	0.104	0.37	CbGaD
Canagliflozin—ALB—breast cancer	0.0911	0.323	CbGaD
Canagliflozin—ABCB1—breast cancer	0.0869	0.308	CbGaD
Canagliflozin—UGT1A9—Irinotecan—breast cancer	0.0374	0.0862	CbGbCtD
Canagliflozin—ABCC2—Tamoxifen—breast cancer	0.0242	0.0559	CbGbCtD
Canagliflozin—ABCB1—Toremifene—breast cancer	0.0216	0.0499	CbGbCtD
Canagliflozin—ABCC2—Paclitaxel—breast cancer	0.0188	0.0435	CbGbCtD
Canagliflozin—CYP3A4—Exemestane—breast cancer	0.0187	0.0431	CbGbCtD
Canagliflozin—ABCC2—Irinotecan—breast cancer	0.0186	0.0429	CbGbCtD
Canagliflozin—ABCC2—Carboplatin—breast cancer	0.0177	0.0409	CbGbCtD
Canagliflozin—ABCC2—Vinblastine—breast cancer	0.0165	0.0382	CbGbCtD
Canagliflozin—CYP3A4—Letrozole—breast cancer	0.0159	0.0367	CbGbCtD
Canagliflozin—ABCB1—Lapatinib—breast cancer	0.0158	0.0364	CbGbCtD
Canagliflozin—CYP3A4—Anastrozole—breast cancer	0.0142	0.0327	CbGbCtD
Canagliflozin—ABCC2—Docetaxel—breast cancer	0.0136	0.0314	CbGbCtD
Canagliflozin—CYP3A4—Toremifene—breast cancer	0.0129	0.0299	CbGbCtD
Canagliflozin—CYP3A4—Fulvestrant—breast cancer	0.012	0.0278	CbGbCtD
Canagliflozin—ALB—Irinotecan—breast cancer	0.0116	0.0267	CbGbCtD
Canagliflozin—ALB—Fluorouracil—breast cancer	0.0111	0.0257	CbGbCtD
Canagliflozin—CYP3A4—Thiotepa—breast cancer	0.0107	0.0248	CbGbCtD
Canagliflozin—ABCC2—Doxorubicin—breast cancer	0.0102	0.0234	CbGbCtD
Canagliflozin—ABCC2—Methotrexate—breast cancer	0.00984	0.0227	CbGbCtD
Canagliflozin—CYP3A4—Ixabepilone—breast cancer	0.00981	0.0226	CbGbCtD
Canagliflozin—CYP3A4—Lapatinib—breast cancer	0.00945	0.0218	CbGbCtD
Canagliflozin—ABCB1—Vinorelbine—breast cancer	0.00875	0.0202	CbGbCtD
Canagliflozin—ABCB1—Tamoxifen—breast cancer	0.00789	0.0182	CbGbCtD
Canagliflozin—ABCB1—Mitoxantrone—breast cancer	0.0077	0.0178	CbGbCtD
Canagliflozin—CYP3A4—Raloxifene—breast cancer	0.00716	0.0165	CbGbCtD
Canagliflozin—ABCB1—Gemcitabine—breast cancer	0.0068	0.0157	CbGbCtD
Canagliflozin—ABCB1—Paclitaxel—breast cancer	0.00614	0.0142	CbGbCtD
Canagliflozin—ALB—Methotrexate—breast cancer	0.00613	0.0142	CbGbCtD
Canagliflozin—ABCB1—Irinotecan—breast cancer	0.00606	0.014	CbGbCtD
Canagliflozin—ABCB1—Vinblastine—breast cancer	0.00539	0.0124	CbGbCtD
Canagliflozin—CYP3A4—Vinorelbine—breast cancer	0.00524	0.0121	CbGbCtD
Canagliflozin—CYP3A4—Tamoxifen—breast cancer	0.00473	0.0109	CbGbCtD
Canagliflozin—CYP3A4—Mitoxantrone—breast cancer	0.00461	0.0106	CbGbCtD
Canagliflozin—ABCB1—Docetaxel—breast cancer	0.00444	0.0103	CbGbCtD
Canagliflozin—CYP3A4—Paclitaxel—breast cancer	0.00368	0.0085	CbGbCtD
Canagliflozin—CYP3A4—Irinotecan—breast cancer	0.00363	0.00838	CbGbCtD
Canagliflozin—SLC5A1—mammary gland—breast cancer	0.00342	0.178	CbGeAlD
Canagliflozin—ABCB1—Doxorubicin—breast cancer	0.00331	0.00764	CbGbCtD
Canagliflozin—CYP3A4—Vinblastine—breast cancer	0.00323	0.00745	CbGbCtD
Canagliflozin—ABCB1—Methotrexate—breast cancer	0.00321	0.0074	CbGbCtD
Canagliflozin—CYP3A4—Docetaxel—breast cancer	0.00266	0.00614	CbGbCtD
Canagliflozin—CYP3A4—Doxorubicin—breast cancer	0.00198	0.00458	CbGbCtD
Canagliflozin—SLC5A1—epithelium—breast cancer	0.0019	0.099	CbGeAlD
Canagliflozin—SLC5A1—endometrium—breast cancer	0.00171	0.0888	CbGeAlD
Canagliflozin—SLC5A2—endocrine gland—breast cancer	0.00158	0.0821	CbGeAlD
Canagliflozin—SLC5A1—pituitary gland—breast cancer	0.00154	0.0803	CbGeAlD
Canagliflozin—UGT2B4—endocrine gland—breast cancer	0.0011	0.0573	CbGeAlD
Canagliflozin—Dapagliflozin—CYP1A1—breast cancer	0.00102	0.343	CrCbGaD
Canagliflozin—ALB—mammary gland—breast cancer	0.000992	0.0516	CbGeAlD
Canagliflozin—Dapagliflozin—CYP2D6—breast cancer	0.000761	0.255	CrCbGaD
Canagliflozin—UGT1A9—endocrine gland—breast cancer	0.000753	0.0392	CbGeAlD
Canagliflozin—Dapagliflozin—CYP3A4—breast cancer	0.000652	0.219	CrCbGaD
Canagliflozin—ORM1—endometrium—breast cancer	0.000565	0.0294	CbGeAlD
Canagliflozin—Dapagliflozin—ABCB1—breast cancer	0.000543	0.182	CrCbGaD
Canagliflozin—ORM1—female reproductive system—breast cancer	0.000468	0.0244	CbGeAlD
Canagliflozin—ORM1—bone marrow—breast cancer	0.000442	0.023	CbGeAlD
Canagliflozin—ALB—adrenal gland—breast cancer	0.000401	0.0208	CbGeAlD
Canagliflozin—ORM1—endocrine gland—breast cancer	0.000396	0.0206	CbGeAlD
Canagliflozin—ABCC2—female reproductive system—breast cancer	0.000385	0.02	CbGeAlD
Canagliflozin—ABCC2—adrenal gland—breast cancer	0.000375	0.0195	CbGeAlD
Canagliflozin—ABCC2—endocrine gland—breast cancer	0.000326	0.0169	CbGeAlD
Canagliflozin—ORM1—lymph node—breast cancer	0.000274	0.0143	CbGeAlD
Canagliflozin—ALB—lymph node—breast cancer	0.00024	0.0125	CbGeAlD
Canagliflozin—ABCB1—embryo—breast cancer	0.000228	0.0119	CbGeAlD
Canagliflozin—ABCC2—lymph node—breast cancer	0.000225	0.0117	CbGeAlD
Canagliflozin—CYP3A4—female reproductive system—breast cancer	0.000195	0.0102	CbGeAlD
Canagliflozin—ABCB1—epithelium—breast cancer	0.000186	0.00969	CbGeAlD
Canagliflozin—ABCB1—endometrium—breast cancer	0.000167	0.00869	CbGeAlD
Canagliflozin—CYP3A4—endocrine gland—breast cancer	0.000165	0.0086	CbGeAlD
Canagliflozin—ABCB1—uterus—breast cancer	0.000154	0.00801	CbGeAlD
Canagliflozin—ABCB1—pituitary gland—breast cancer	0.000151	0.00786	CbGeAlD
Canagliflozin—ABCB1—adipose tissue—breast cancer	0.00015	0.00783	CbGeAlD
Canagliflozin—ABCB1—female reproductive system—breast cancer	0.000138	0.0072	CbGeAlD
Canagliflozin—ABCB1—adrenal gland—breast cancer	0.000135	0.00702	CbGeAlD
Canagliflozin—ABCB1—bone marrow—breast cancer	0.000131	0.0068	CbGeAlD
Canagliflozin—ABCB1—female gonad—breast cancer	0.000126	0.00655	CbGeAlD
Canagliflozin—ABCB1—endocrine gland—breast cancer	0.000117	0.00609	CbGeAlD
Canagliflozin—Infection—Fluorouracil—breast cancer	8.89e-05	0.000614	CcSEcCtD
Canagliflozin—Renal failure acute—Doxorubicin—breast cancer	8.89e-05	0.000614	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Thiotepa—breast cancer	8.85e-05	0.000611	CcSEcCtD
Canagliflozin—Skin disorder—Gemcitabine—breast cancer	8.84e-05	0.000611	CcSEcCtD
Canagliflozin—Nausea—Chlorambucil—breast cancer	8.84e-05	0.00061	CcSEcCtD
Canagliflozin—Nervous system disorder—Fluorouracil—breast cancer	8.78e-05	0.000606	CcSEcCtD
Canagliflozin—Dizziness—Tamoxifen—breast cancer	8.76e-05	0.000605	CcSEcCtD
Canagliflozin—Hypotension—Irinotecan—breast cancer	8.73e-05	0.000603	CcSEcCtD
Canagliflozin—Hypotension—Mitoxantrone—breast cancer	8.73e-05	0.000603	CcSEcCtD
Canagliflozin—Urinary tract disorder—Capecitabine—breast cancer	8.7e-05	0.0006	CcSEcCtD
Canagliflozin—Urethral disorder—Capecitabine—breast cancer	8.63e-05	0.000596	CcSEcCtD
Canagliflozin—Urticaria—Thiotepa—breast cancer	8.6e-05	0.000594	CcSEcCtD
Canagliflozin—Breast disorder—Methotrexate—breast cancer	8.56e-05	0.000591	CcSEcCtD
Canagliflozin—Abdominal pain—Thiotepa—breast cancer	8.56e-05	0.000591	CcSEcCtD
Canagliflozin—Angioedema—Paclitaxel—breast cancer	8.53e-05	0.000589	CcSEcCtD
Canagliflozin—Hypotension—Gemcitabine—breast cancer	8.51e-05	0.000587	CcSEcCtD
Canagliflozin—Hypoglycaemia—Doxorubicin—breast cancer	8.41e-05	0.000581	CcSEcCtD
Canagliflozin—Syncope—Paclitaxel—breast cancer	8.38e-05	0.000578	CcSEcCtD
Canagliflozin—Dizziness—Goserelin—breast cancer	8.37e-05	0.000578	CcSEcCtD
Canagliflozin—Hypotension—Fluorouracil—breast cancer	8.36e-05	0.000578	CcSEcCtD
Canagliflozin—Rash—Tamoxifen—breast cancer	8.35e-05	0.000577	CcSEcCtD
Canagliflozin—Hypersensitivity—Vinorelbine—breast cancer	8.35e-05	0.000577	CcSEcCtD
Canagliflozin—Dermatitis—Tamoxifen—breast cancer	8.35e-05	0.000576	CcSEcCtD
Canagliflozin—Blood creatinine increased—Epirubicin—breast cancer	8.31e-05	0.000574	CcSEcCtD
Canagliflozin—Angiopathy—Docetaxel—breast cancer	8.25e-05	0.00057	CcSEcCtD
Canagliflozin—Dehydration—Epirubicin—breast cancer	8.25e-05	0.000569	CcSEcCtD
Canagliflozin—Loss of consciousness—Paclitaxel—breast cancer	8.21e-05	0.000567	CcSEcCtD
Canagliflozin—Rash—Melphalan—breast cancer	8.18e-05	0.000565	CcSEcCtD
Canagliflozin—Dermatitis—Melphalan—breast cancer	8.17e-05	0.000564	CcSEcCtD
Canagliflozin—Asthenia—Vinorelbine—breast cancer	8.13e-05	0.000562	CcSEcCtD
Canagliflozin—Nausea—Vinblastine—breast cancer	8.1e-05	0.000559	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Epirubicin—breast cancer	8.1e-05	0.000559	CcSEcCtD
Canagliflozin—Convulsion—Paclitaxel—breast cancer	8.09e-05	0.000559	CcSEcCtD
Canagliflozin—ABCB1—lymph node—breast cancer	8.09e-05	0.00421	CbGeAlD
Canagliflozin—Gastrointestinal disorder—Irinotecan—breast cancer	8.07e-05	0.000557	CcSEcCtD
Canagliflozin—Fatigue—Irinotecan—breast cancer	8.06e-05	0.000556	CcSEcCtD
Canagliflozin—Fatigue—Mitoxantrone—breast cancer	8.06e-05	0.000556	CcSEcCtD
Canagliflozin—Pancreatitis—Methotrexate—breast cancer	8.03e-05	0.000554	CcSEcCtD
Canagliflozin—Pruritus—Vinorelbine—breast cancer	8.02e-05	0.000554	CcSEcCtD
Canagliflozin—Breast disorder—Epirubicin—breast cancer	8.01e-05	0.000553	CcSEcCtD
Canagliflozin—Constipation—Mitoxantrone—breast cancer	7.99e-05	0.000552	CcSEcCtD
Canagliflozin—Constipation—Irinotecan—breast cancer	7.99e-05	0.000552	CcSEcCtD
Canagliflozin—Angiopathy—Capecitabine—breast cancer	7.99e-05	0.000552	CcSEcCtD
Canagliflozin—Rash—Goserelin—breast cancer	7.98e-05	0.000551	CcSEcCtD
Canagliflozin—Hypersensitivity—Thiotepa—breast cancer	7.97e-05	0.000551	CcSEcCtD
Canagliflozin—Dermatitis—Goserelin—breast cancer	7.97e-05	0.00055	CcSEcCtD
Canagliflozin—Malnutrition—Docetaxel—breast cancer	7.92e-05	0.000547	CcSEcCtD
Canagliflozin—Erythema—Docetaxel—breast cancer	7.92e-05	0.000547	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—breast cancer	7.9e-05	0.000545	CcSEcCtD
Canagliflozin—Nausea—Tamoxifen—breast cancer	7.87e-05	0.000543	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Gemcitabine—breast cancer	7.86e-05	0.000543	CcSEcCtD
Canagliflozin—Fatigue—Gemcitabine—breast cancer	7.85e-05	0.000542	CcSEcCtD
Canagliflozin—Constipation—Gemcitabine—breast cancer	7.79e-05	0.000538	CcSEcCtD
Canagliflozin—Dry mouth—Paclitaxel—breast cancer	7.78e-05	0.000537	CcSEcCtD
Canagliflozin—Asthenia—Thiotepa—breast cancer	7.77e-05	0.000536	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Fluorouracil—breast cancer	7.73e-05	0.000534	CcSEcCtD
Canagliflozin—Nausea—Melphalan—breast cancer	7.7e-05	0.000532	CcSEcCtD
Canagliflozin—Blood creatinine increased—Doxorubicin—breast cancer	7.69e-05	0.000531	CcSEcCtD
Canagliflozin—Erythema—Capecitabine—breast cancer	7.66e-05	0.000529	CcSEcCtD
Canagliflozin—Malnutrition—Capecitabine—breast cancer	7.66e-05	0.000529	CcSEcCtD
Canagliflozin—Pruritus—Thiotepa—breast cancer	7.66e-05	0.000529	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Mitoxantrone—breast cancer	7.64e-05	0.000528	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Irinotecan—breast cancer	7.64e-05	0.000528	CcSEcCtD
Canagliflozin—Dehydration—Doxorubicin—breast cancer	7.63e-05	0.000527	CcSEcCtD
Canagliflozin—Infection—Paclitaxel—breast cancer	7.57e-05	0.000523	CcSEcCtD
Canagliflozin—Nausea—Goserelin—breast cancer	7.52e-05	0.000519	CcSEcCtD
Canagliflozin—Pancreatitis—Epirubicin—breast cancer	7.51e-05	0.000519	CcSEcCtD
Canagliflozin—Shock—Paclitaxel—breast cancer	7.5e-05	0.000518	CcSEcCtD
Canagliflozin—Dizziness—Vinorelbine—breast cancer	7.49e-05	0.000518	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Doxorubicin—breast cancer	7.49e-05	0.000517	CcSEcCtD
Canagliflozin—Nervous system disorder—Paclitaxel—breast cancer	7.48e-05	0.000516	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Methotrexate—breast cancer	7.47e-05	0.000516	CcSEcCtD
Canagliflozin—Urticaria—Mitoxantrone—breast cancer	7.42e-05	0.000513	CcSEcCtD
Canagliflozin—Breast disorder—Doxorubicin—breast cancer	7.41e-05	0.000512	CcSEcCtD
Canagliflozin—Skin disorder—Paclitaxel—breast cancer	7.4e-05	0.000511	CcSEcCtD
Canagliflozin—Abdominal pain—Mitoxantrone—breast cancer	7.39e-05	0.00051	CcSEcCtD
Canagliflozin—Abdominal pain—Irinotecan—breast cancer	7.39e-05	0.00051	CcSEcCtD
Canagliflozin—Dizziness—Thiotepa—breast cancer	7.16e-05	0.000494	CcSEcCtD
Canagliflozin—Rash—Vinorelbine—breast cancer	7.15e-05	0.000493	CcSEcCtD
Canagliflozin—Dermatitis—Vinorelbine—breast cancer	7.14e-05	0.000493	CcSEcCtD
Canagliflozin—Hypotension—Paclitaxel—breast cancer	7.12e-05	0.000492	CcSEcCtD
Canagliflozin—Urticaria—Fluorouracil—breast cancer	7.11e-05	0.000491	CcSEcCtD
Canagliflozin—Syncope—Docetaxel—breast cancer	7.1e-05	0.00049	CcSEcCtD
Canagliflozin—Pollakiuria—Epirubicin—breast cancer	7.08e-05	0.000489	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Epirubicin—breast cancer	6.99e-05	0.000483	CcSEcCtD
Canagliflozin—Loss of consciousness—Docetaxel—breast cancer	6.96e-05	0.00048	CcSEcCtD
Canagliflozin—Pancreatitis—Doxorubicin—breast cancer	6.95e-05	0.00048	CcSEcCtD
Canagliflozin—Hypersensitivity—Irinotecan—breast cancer	6.89e-05	0.000476	CcSEcCtD
Canagliflozin—Hypersensitivity—Mitoxantrone—breast cancer	6.89e-05	0.000476	CcSEcCtD
Canagliflozin—Syncope—Capecitabine—breast cancer	6.87e-05	0.000475	CcSEcCtD
Canagliflozin—Convulsion—Docetaxel—breast cancer	6.86e-05	0.000474	CcSEcCtD
Canagliflozin—Rash—Thiotepa—breast cancer	6.82e-05	0.000471	CcSEcCtD
Canagliflozin—Dermatitis—Thiotepa—breast cancer	6.82e-05	0.000471	CcSEcCtD
Canagliflozin—Loss of consciousness—Capecitabine—breast cancer	6.74e-05	0.000465	CcSEcCtD
Canagliflozin—Nausea—Vinorelbine—breast cancer	6.73e-05	0.000465	CcSEcCtD
Canagliflozin—Asthenia—Mitoxantrone—breast cancer	6.71e-05	0.000463	CcSEcCtD
Canagliflozin—Asthenia—Irinotecan—breast cancer	6.71e-05	0.000463	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	6.69e-05	0.000462	CcSEcCtD
Canagliflozin—Urinary tract infection—Epirubicin—breast cancer	6.64e-05	0.000459	CcSEcCtD
Canagliflozin—Hypersensitivity—Fluorouracil—breast cancer	6.6e-05	0.000455	CcSEcCtD
Canagliflozin—Dry mouth—Docetaxel—breast cancer	6.59e-05	0.000455	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Paclitaxel—breast cancer	6.58e-05	0.000454	CcSEcCtD
Canagliflozin—Fatigue—Paclitaxel—breast cancer	6.57e-05	0.000454	CcSEcCtD
Canagliflozin—Pollakiuria—Doxorubicin—breast cancer	6.55e-05	0.000452	CcSEcCtD
Canagliflozin—Asthenia—Gemcitabine—breast cancer	6.53e-05	0.000451	CcSEcCtD
Canagliflozin—Constipation—Paclitaxel—breast cancer	6.52e-05	0.00045	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	6.48e-05	0.000448	CcSEcCtD
Canagliflozin—Urinary tract disorder—Methotrexate—breast cancer	6.47e-05	0.000447	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Doxorubicin—breast cancer	6.47e-05	0.000447	CcSEcCtD
Canagliflozin—Pruritus—Gemcitabine—breast cancer	6.44e-05	0.000445	CcSEcCtD
Canagliflozin—Nausea—Thiotepa—breast cancer	6.43e-05	0.000444	CcSEcCtD
Canagliflozin—Urethral disorder—Methotrexate—breast cancer	6.43e-05	0.000444	CcSEcCtD
Canagliflozin—Infection—Docetaxel—breast cancer	6.42e-05	0.000443	CcSEcCtD
Canagliflozin—Dry mouth—Capecitabine—breast cancer	6.38e-05	0.000441	CcSEcCtD
Canagliflozin—Shock—Docetaxel—breast cancer	6.36e-05	0.000439	CcSEcCtD
Canagliflozin—Nervous system disorder—Docetaxel—breast cancer	6.34e-05	0.000438	CcSEcCtD
Canagliflozin—Pruritus—Fluorouracil—breast cancer	6.33e-05	0.000437	CcSEcCtD
Canagliflozin—Skin disorder—Docetaxel—breast cancer	6.28e-05	0.000433	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Paclitaxel—breast cancer	6.23e-05	0.00043	CcSEcCtD
Canagliflozin—Infection—Capecitabine—breast cancer	6.21e-05	0.000429	CcSEcCtD
Canagliflozin—Dizziness—Irinotecan—breast cancer	6.18e-05	0.000427	CcSEcCtD
Canagliflozin—Shock—Capecitabine—breast cancer	6.15e-05	0.000425	CcSEcCtD
Canagliflozin—Urinary tract infection—Doxorubicin—breast cancer	6.15e-05	0.000424	CcSEcCtD
Canagliflozin—Nervous system disorder—Capecitabine—breast cancer	6.13e-05	0.000424	CcSEcCtD
Canagliflozin—Skin disorder—Capecitabine—breast cancer	6.08e-05	0.00042	CcSEcCtD
Canagliflozin—Urinary tract disorder—Epirubicin—breast cancer	6.06e-05	0.000418	CcSEcCtD
Canagliflozin—Urticaria—Paclitaxel—breast cancer	6.06e-05	0.000418	CcSEcCtD
Canagliflozin—Hypotension—Docetaxel—breast cancer	6.04e-05	0.000417	CcSEcCtD
Canagliflozin—Abdominal pain—Paclitaxel—breast cancer	6.03e-05	0.000416	CcSEcCtD
Canagliflozin—Urethral disorder—Epirubicin—breast cancer	6.01e-05	0.000415	CcSEcCtD
Canagliflozin—Angiopathy—Methotrexate—breast cancer	5.95e-05	0.000411	CcSEcCtD
Canagliflozin—Dizziness—Fluorouracil—breast cancer	5.92e-05	0.000409	CcSEcCtD
Canagliflozin—Rash—Irinotecan—breast cancer	5.89e-05	0.000407	CcSEcCtD
Canagliflozin—Rash—Mitoxantrone—breast cancer	5.89e-05	0.000407	CcSEcCtD
Canagliflozin—Dermatitis—Mitoxantrone—breast cancer	5.89e-05	0.000407	CcSEcCtD
Canagliflozin—Dermatitis—Irinotecan—breast cancer	5.89e-05	0.000407	CcSEcCtD
Canagliflozin—Hypotension—Capecitabine—breast cancer	5.85e-05	0.000404	CcSEcCtD
Canagliflozin—Rash—Gemcitabine—breast cancer	5.74e-05	0.000396	CcSEcCtD
Canagliflozin—Dermatitis—Gemcitabine—breast cancer	5.74e-05	0.000396	CcSEcCtD
Canagliflozin—Erythema—Methotrexate—breast cancer	5.71e-05	0.000394	CcSEcCtD
Canagliflozin—Malnutrition—Methotrexate—breast cancer	5.71e-05	0.000394	CcSEcCtD
Canagliflozin—Rash—Fluorouracil—breast cancer	5.64e-05	0.00039	CcSEcCtD
Canagliflozin—Dermatitis—Fluorouracil—breast cancer	5.64e-05	0.000389	CcSEcCtD
Canagliflozin—Hypersensitivity—Paclitaxel—breast cancer	5.62e-05	0.000388	CcSEcCtD
Canagliflozin—Urinary tract disorder—Doxorubicin—breast cancer	5.6e-05	0.000387	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Docetaxel—breast cancer	5.58e-05	0.000385	CcSEcCtD
Canagliflozin—Fatigue—Docetaxel—breast cancer	5.57e-05	0.000385	CcSEcCtD
Canagliflozin—Angiopathy—Epirubicin—breast cancer	5.57e-05	0.000384	CcSEcCtD
Canagliflozin—Urethral disorder—Doxorubicin—breast cancer	5.56e-05	0.000384	CcSEcCtD
Canagliflozin—Nausea—Mitoxantrone—breast cancer	5.55e-05	0.000383	CcSEcCtD
Canagliflozin—Nausea—Irinotecan—breast cancer	5.55e-05	0.000383	CcSEcCtD
Canagliflozin—Constipation—Docetaxel—breast cancer	5.52e-05	0.000382	CcSEcCtD
Canagliflozin—Asthenia—Paclitaxel—breast cancer	5.47e-05	0.000378	CcSEcCtD
Canagliflozin—Nausea—Gemcitabine—breast cancer	5.41e-05	0.000373	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Capecitabine—breast cancer	5.4e-05	0.000373	CcSEcCtD
Canagliflozin—Fatigue—Capecitabine—breast cancer	5.39e-05	0.000372	CcSEcCtD
Canagliflozin—Pruritus—Paclitaxel—breast cancer	5.39e-05	0.000372	CcSEcCtD
Canagliflozin—Constipation—Capecitabine—breast cancer	5.35e-05	0.000369	CcSEcCtD
Canagliflozin—Erythema—Epirubicin—breast cancer	5.34e-05	0.000369	CcSEcCtD
Canagliflozin—Malnutrition—Epirubicin—breast cancer	5.34e-05	0.000369	CcSEcCtD
Canagliflozin—Nausea—Fluorouracil—breast cancer	5.32e-05	0.000367	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Docetaxel—breast cancer	5.28e-05	0.000365	CcSEcCtD
Canagliflozin—Angiopathy—Doxorubicin—breast cancer	5.15e-05	0.000356	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Capecitabine—breast cancer	5.12e-05	0.000353	CcSEcCtD
Canagliflozin—Abdominal pain—Docetaxel—breast cancer	5.11e-05	0.000353	CcSEcCtD
Canagliflozin—Dizziness—Paclitaxel—breast cancer	5.04e-05	0.000348	CcSEcCtD
Canagliflozin—Urticaria—Capecitabine—breast cancer	4.97e-05	0.000343	CcSEcCtD
Canagliflozin—Abdominal pain—Capecitabine—breast cancer	4.94e-05	0.000341	CcSEcCtD
Canagliflozin—Convulsion—Methotrexate—breast cancer	4.94e-05	0.000341	CcSEcCtD
Canagliflozin—Malnutrition—Doxorubicin—breast cancer	4.94e-05	0.000341	CcSEcCtD
Canagliflozin—Erythema—Doxorubicin—breast cancer	4.94e-05	0.000341	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	4.82e-05	0.000333	CcSEcCtD
Canagliflozin—Rash—Paclitaxel—breast cancer	4.81e-05	0.000332	CcSEcCtD
Canagliflozin—Dermatitis—Paclitaxel—breast cancer	4.8e-05	0.000332	CcSEcCtD
Canagliflozin—Syncope—Epirubicin—breast cancer	4.79e-05	0.000331	CcSEcCtD
Canagliflozin—Hypersensitivity—Docetaxel—breast cancer	4.76e-05	0.000329	CcSEcCtD
Canagliflozin—Loss of consciousness—Epirubicin—breast cancer	4.69e-05	0.000324	CcSEcCtD
Canagliflozin—Asthenia—Docetaxel—breast cancer	4.64e-05	0.00032	CcSEcCtD
Canagliflozin—Convulsion—Epirubicin—breast cancer	4.63e-05	0.000319	CcSEcCtD
Canagliflozin—Infection—Methotrexate—breast cancer	4.63e-05	0.000319	CcSEcCtD
Canagliflozin—Hypersensitivity—Capecitabine—breast cancer	4.61e-05	0.000318	CcSEcCtD
Canagliflozin—Pruritus—Docetaxel—breast cancer	4.57e-05	0.000316	CcSEcCtD
Canagliflozin—Nervous system disorder—Methotrexate—breast cancer	4.57e-05	0.000315	CcSEcCtD
Canagliflozin—Nausea—Paclitaxel—breast cancer	4.53e-05	0.000313	CcSEcCtD
Canagliflozin—Skin disorder—Methotrexate—breast cancer	4.52e-05	0.000312	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	4.51e-05	0.000312	CcSEcCtD
Canagliflozin—Asthenia—Capecitabine—breast cancer	4.49e-05	0.00031	CcSEcCtD
Canagliflozin—Dry mouth—Epirubicin—breast cancer	4.45e-05	0.000307	CcSEcCtD
Canagliflozin—Syncope—Doxorubicin—breast cancer	4.43e-05	0.000306	CcSEcCtD
Canagliflozin—Pruritus—Capecitabine—breast cancer	4.43e-05	0.000306	CcSEcCtD
Canagliflozin—Hypotension—Methotrexate—breast cancer	4.35e-05	0.0003	CcSEcCtD
Canagliflozin—Loss of consciousness—Doxorubicin—breast cancer	4.34e-05	0.0003	CcSEcCtD
Canagliflozin—Infection—Epirubicin—breast cancer	4.33e-05	0.000299	CcSEcCtD
Canagliflozin—Shock—Epirubicin—breast cancer	4.29e-05	0.000296	CcSEcCtD
Canagliflozin—Convulsion—Doxorubicin—breast cancer	4.28e-05	0.000296	CcSEcCtD
Canagliflozin—Nervous system disorder—Epirubicin—breast cancer	4.27e-05	0.000295	CcSEcCtD
Canagliflozin—Dizziness—Docetaxel—breast cancer	4.27e-05	0.000295	CcSEcCtD
Canagliflozin—Skin disorder—Epirubicin—breast cancer	4.23e-05	0.000292	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	4.18e-05	0.000288	CcSEcCtD
Canagliflozin—Dizziness—Capecitabine—breast cancer	4.14e-05	0.000286	CcSEcCtD
Canagliflozin—Dry mouth—Doxorubicin—breast cancer	4.11e-05	0.000284	CcSEcCtD
Canagliflozin—Rash—Docetaxel—breast cancer	4.07e-05	0.000281	CcSEcCtD
Canagliflozin—Hypotension—Epirubicin—breast cancer	4.07e-05	0.000281	CcSEcCtD
Canagliflozin—Dermatitis—Docetaxel—breast cancer	4.07e-05	0.000281	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Methotrexate—breast cancer	4.02e-05	0.000278	CcSEcCtD
Canagliflozin—Fatigue—Methotrexate—breast cancer	4.01e-05	0.000277	CcSEcCtD
Canagliflozin—Infection—Doxorubicin—breast cancer	4.01e-05	0.000277	CcSEcCtD
Canagliflozin—Shock—Doxorubicin—breast cancer	3.97e-05	0.000274	CcSEcCtD
Canagliflozin—Nervous system disorder—Doxorubicin—breast cancer	3.95e-05	0.000273	CcSEcCtD
Canagliflozin—Rash—Capecitabine—breast cancer	3.94e-05	0.000272	CcSEcCtD
Canagliflozin—Dermatitis—Capecitabine—breast cancer	3.94e-05	0.000272	CcSEcCtD
Canagliflozin—Skin disorder—Doxorubicin—breast cancer	3.92e-05	0.00027	CcSEcCtD
Canagliflozin—Nausea—Docetaxel—breast cancer	3.84e-05	0.000265	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Methotrexate—breast cancer	3.81e-05	0.000263	CcSEcCtD
Canagliflozin—Hypotension—Doxorubicin—breast cancer	3.77e-05	0.00026	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Epirubicin—breast cancer	3.76e-05	0.00026	CcSEcCtD
Canagliflozin—Fatigue—Epirubicin—breast cancer	3.76e-05	0.000259	CcSEcCtD
Canagliflozin—Constipation—Epirubicin—breast cancer	3.73e-05	0.000257	CcSEcCtD
Canagliflozin—Nausea—Capecitabine—breast cancer	3.72e-05	0.000257	CcSEcCtD
Canagliflozin—Urticaria—Methotrexate—breast cancer	3.7e-05	0.000255	CcSEcCtD
Canagliflozin—Abdominal pain—Methotrexate—breast cancer	3.68e-05	0.000254	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Epirubicin—breast cancer	3.56e-05	0.000246	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Doxorubicin—breast cancer	3.48e-05	0.00024	CcSEcCtD
Canagliflozin—Fatigue—Doxorubicin—breast cancer	3.48e-05	0.00024	CcSEcCtD
Canagliflozin—Urticaria—Epirubicin—breast cancer	3.46e-05	0.000239	CcSEcCtD
Canagliflozin—Constipation—Doxorubicin—breast cancer	3.45e-05	0.000238	CcSEcCtD
Canagliflozin—Abdominal pain—Epirubicin—breast cancer	3.44e-05	0.000238	CcSEcCtD
Canagliflozin—Hypersensitivity—Methotrexate—breast cancer	3.43e-05	0.000237	CcSEcCtD
Canagliflozin—Asthenia—Methotrexate—breast cancer	3.34e-05	0.000231	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Doxorubicin—breast cancer	3.3e-05	0.000228	CcSEcCtD
Canagliflozin—Pruritus—Methotrexate—breast cancer	3.29e-05	0.000228	CcSEcCtD
Canagliflozin—Hypersensitivity—Epirubicin—breast cancer	3.21e-05	0.000222	CcSEcCtD
Canagliflozin—Urticaria—Doxorubicin—breast cancer	3.2e-05	0.000221	CcSEcCtD
Canagliflozin—Abdominal pain—Doxorubicin—breast cancer	3.19e-05	0.00022	CcSEcCtD
Canagliflozin—Asthenia—Epirubicin—breast cancer	3.13e-05	0.000216	CcSEcCtD
Canagliflozin—Pruritus—Epirubicin—breast cancer	3.08e-05	0.000213	CcSEcCtD
Canagliflozin—Dizziness—Methotrexate—breast cancer	3.08e-05	0.000213	CcSEcCtD
Canagliflozin—Hypersensitivity—Doxorubicin—breast cancer	2.97e-05	0.000205	CcSEcCtD
Canagliflozin—Rash—Methotrexate—breast cancer	2.94e-05	0.000203	CcSEcCtD
Canagliflozin—Dermatitis—Methotrexate—breast cancer	2.93e-05	0.000203	CcSEcCtD
Canagliflozin—Asthenia—Doxorubicin—breast cancer	2.89e-05	0.0002	CcSEcCtD
Canagliflozin—Dizziness—Epirubicin—breast cancer	2.88e-05	0.000199	CcSEcCtD
Canagliflozin—Pruritus—Doxorubicin—breast cancer	2.85e-05	0.000197	CcSEcCtD
Canagliflozin—Nausea—Methotrexate—breast cancer	2.77e-05	0.000191	CcSEcCtD
Canagliflozin—Rash—Epirubicin—breast cancer	2.75e-05	0.00019	CcSEcCtD
Canagliflozin—Dermatitis—Epirubicin—breast cancer	2.75e-05	0.00019	CcSEcCtD
Canagliflozin—Dizziness—Doxorubicin—breast cancer	2.67e-05	0.000184	CcSEcCtD
Canagliflozin—Nausea—Epirubicin—breast cancer	2.59e-05	0.000179	CcSEcCtD
Canagliflozin—Rash—Doxorubicin—breast cancer	2.54e-05	0.000176	CcSEcCtD
Canagliflozin—Dermatitis—Doxorubicin—breast cancer	2.54e-05	0.000175	CcSEcCtD
Canagliflozin—Nausea—Doxorubicin—breast cancer	2.4e-05	0.000165	CcSEcCtD
Canagliflozin—UGT1A9—Metabolism—GSTM1—breast cancer	5.55e-06	4.73e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PLA2G4A—breast cancer	5.55e-06	4.73e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CA9—breast cancer	5.54e-06	4.73e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTA4—breast cancer	5.54e-06	4.73e-05	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—AKT1—breast cancer	5.5e-06	4.69e-05	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—AKT1—breast cancer	5.5e-06	4.69e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NOS2—breast cancer	5.49e-06	4.69e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—breast cancer	5.47e-06	4.67e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTA2—breast cancer	5.4e-06	4.61e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GPX2—breast cancer	5.4e-06	4.61e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SULT1A1—breast cancer	5.34e-06	4.55e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GPX4—breast cancer	5.34e-06	4.55e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CG—breast cancer	5.32e-06	4.54e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CAV1—breast cancer	5.32e-06	4.54e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GPX1—breast cancer	5.31e-06	4.53e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SHMT1—breast cancer	5.3e-06	4.52e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CDA—breast cancer	5.3e-06	4.52e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP1A1—breast cancer	5.26e-06	4.49e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—EGF—breast cancer	5.26e-06	4.49e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ERCC2—breast cancer	5.22e-06	4.45e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—IDH1—breast cancer	5.21e-06	4.45e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTA1—breast cancer	5.21e-06	4.45e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—breast cancer	5.21e-06	4.44e-05	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CA—breast cancer	5.2e-06	4.44e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—breast cancer	5.17e-06	4.41e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—DPYD—breast cancer	5.16e-06	4.4e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—MED12—breast cancer	5.16e-06	4.4e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NAT2—breast cancer	5.15e-06	4.4e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC2A5—breast cancer	5.1e-06	4.35e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLCO1B1—breast cancer	5.1e-06	4.35e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ALDOA—breast cancer	5.08e-06	4.33e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NCOA3—breast cancer	4.93e-06	4.21e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APRT—breast cancer	4.93e-06	4.2e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—MTHFR—breast cancer	4.9e-06	4.18e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC2A2—breast cancer	4.9e-06	4.18e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IGF1—breast cancer	4.87e-06	4.16e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT2—breast cancer	4.87e-06	4.15e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	4.84e-06	4.13e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CA—breast cancer	4.82e-06	4.11e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CPT1A—breast cancer	4.8e-06	4.09e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCG2—breast cancer	4.8e-06	4.09e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—MTR—breast cancer	4.8e-06	4.09e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—breast cancer	4.75e-06	4.05e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HPGDS—breast cancer	4.7e-06	4.01e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CD—breast cancer	4.68e-06	3.99e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HBA1—breast cancer	4.67e-06	3.99e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ESRRA—breast cancer	4.63e-06	3.95e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ANGPTL4—breast cancer	4.63e-06	3.95e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SERPINE1—breast cancer	4.63e-06	3.95e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—breast cancer	4.59e-06	3.92e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTT1—breast cancer	4.56e-06	3.89e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ACHE—breast cancer	4.56e-06	3.89e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CAV1—breast cancer	4.52e-06	3.86e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MED12—breast cancer	4.52e-06	3.86e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—DPYD—breast cancer	4.52e-06	3.86e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALDOA—breast cancer	4.45e-06	3.8e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NOS3—breast cancer	4.42e-06	3.77e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HADHB—breast cancer	4.39e-06	3.75e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPI—breast cancer	4.39e-06	3.75e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	4.32e-06	3.69e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NCOA3—breast cancer	4.32e-06	3.68e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP17A1—breast cancer	4.32e-06	3.68e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC2A2—breast cancer	4.29e-06	3.66e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS1—breast cancer	4.27e-06	3.65e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ENO1—breast cancer	4.27e-06	3.65e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	4.26e-06	3.63e-05	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—AKT1—breast cancer	4.25e-06	3.62e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MTR—breast cancer	4.2e-06	3.58e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ABCG2—breast cancer	4.2e-06	3.58e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CPT1A—breast cancer	4.2e-06	3.58e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP2D6—breast cancer	4.19e-06	3.58e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALDH7A1—breast cancer	4.19e-06	3.57e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALDH1A1—breast cancer	4.19e-06	3.57e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—RAF1—breast cancer	4.18e-06	3.56e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HPGDS—breast cancer	4.12e-06	3.52e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CG—breast cancer	4.12e-06	3.52e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NCOA2—breast cancer	4.11e-06	3.51e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HBA1—breast cancer	4.1e-06	3.49e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CB—breast cancer	4.08e-06	3.48e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—UMPS—breast cancer	4.02e-06	3.43e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ADSL—breast cancer	4.02e-06	3.43e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NME1—breast cancer	4.02e-06	3.43e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PHGDH—breast cancer	4.02e-06	3.43e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—FHL2—breast cancer	4.02e-06	3.43e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTT1—breast cancer	4e-06	3.41e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ACHE—breast cancer	4e-06	3.41e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—FASN—breast cancer	3.99e-06	3.4e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—BCHE—breast cancer	3.97e-06	3.39e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—BRIP1—breast cancer	3.94e-06	3.36e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—LDHB—breast cancer	3.94e-06	3.36e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HPSE—breast cancer	3.94e-06	3.36e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—AKT1—breast cancer	3.94e-06	3.36e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC5A5—breast cancer	3.93e-06	3.35e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—breast cancer	3.88e-06	3.31e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC2A1—breast cancer	3.79e-06	3.23e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NQO1—breast cancer	3.79e-06	3.23e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP17A1—breast cancer	3.78e-06	3.23e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS1—breast cancer	3.75e-06	3.19e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ENO1—breast cancer	3.75e-06	3.19e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IL2—breast cancer	3.74e-06	3.19e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HMMR—breast cancer	3.74e-06	3.19e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCC1—breast cancer	3.74e-06	3.19e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTA3—breast cancer	3.74e-06	3.19e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	3.71e-06	3.17e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP3A4—breast cancer	3.7e-06	3.15e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	3.68e-06	3.14e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP2D6—breast cancer	3.67e-06	3.13e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP1B1—breast cancer	3.63e-06	3.1e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CD—breast cancer	3.62e-06	3.09e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPARGC1B—breast cancer	3.62e-06	3.09e-05	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—RAF1—breast cancer	3.62e-06	3.08e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NCOA2—breast cancer	3.61e-06	3.08e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALB—breast cancer	3.58e-06	3.05e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HSP90AA1—breast cancer	3.56e-06	3.04e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—breast cancer	3.5e-06	2.99e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—FASN—breast cancer	3.5e-06	2.98e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—BCHE—breast cancer	3.48e-06	2.97e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NCOA1—breast cancer	3.47e-06	2.96e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC5A5—breast cancer	3.44e-06	2.93e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NOS3—breast cancer	3.42e-06	2.92e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—STK11—breast cancer	3.42e-06	2.91e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP19A1—breast cancer	3.42e-06	2.91e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTA4—breast cancer	3.42e-06	2.91e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CA9—breast cancer	3.42e-06	2.91e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTA2—breast cancer	3.33e-06	2.84e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPX2—breast cancer	3.33e-06	2.84e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC2A1—breast cancer	3.32e-06	2.83e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NQO1—breast cancer	3.32e-06	2.83e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SULT1A1—breast cancer	3.29e-06	2.8e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPX4—breast cancer	3.29e-06	2.8e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SRC—breast cancer	3.27e-06	2.79e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP3A4—breast cancer	3.24e-06	2.76e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTA1—breast cancer	3.21e-06	2.74e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—IDH1—breast cancer	3.21e-06	2.74e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTEN—breast cancer	3.21e-06	2.74e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP1B1—breast cancer	3.18e-06	2.72e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—breast cancer	3.18e-06	2.71e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—COMT—breast cancer	3.18e-06	2.71e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NAT2—breast cancer	3.18e-06	2.71e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—RAF1—breast cancer	3.17e-06	2.7e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTP1—breast cancer	3.16e-06	2.7e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CB—breast cancer	3.16e-06	2.69e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS2—breast cancer	3.13e-06	2.67e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HSP90AA1—breast cancer	3.12e-06	2.66e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HMOX1—breast cancer	3.12e-06	2.66e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ITPR1—breast cancer	3.11e-06	2.65e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NCOA1—breast cancer	3.04e-06	2.59e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MAPK3—breast cancer	3.01e-06	2.57e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP19A1—breast cancer	2.99e-06	2.55e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—STK11—breast cancer	2.99e-06	2.55e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCB1—breast cancer	2.99e-06	2.55e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TYMS—breast cancer	2.94e-06	2.51e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TGFB1—breast cancer	2.92e-06	2.49e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NCOR1—breast cancer	2.91e-06	2.48e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PLA2G4A—breast cancer	2.91e-06	2.48e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTM1—breast cancer	2.91e-06	2.48e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MED12—breast cancer	2.78e-06	2.38e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—DPYD—breast cancer	2.78e-06	2.38e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—COMT—breast cancer	2.78e-06	2.37e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GPX1—breast cancer	2.78e-06	2.37e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTP1—breast cancer	2.77e-06	2.36e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP1A1—breast cancer	2.75e-06	2.35e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALDOA—breast cancer	2.74e-06	2.34e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HMOX1—breast cancer	2.73e-06	2.33e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ERCC2—breast cancer	2.73e-06	2.33e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTEN—breast cancer	2.73e-06	2.33e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ITPR1—breast cancer	2.73e-06	2.33e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—KRAS—breast cancer	2.71e-06	2.31e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NCOA3—breast cancer	2.66e-06	2.27e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC2A2—breast cancer	2.64e-06	2.25e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCG2—breast cancer	2.59e-06	2.21e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MTR—breast cancer	2.59e-06	2.21e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CPT1A—breast cancer	2.59e-06	2.21e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TYMS—breast cancer	2.58e-06	2.2e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—MTHFR—breast cancer	2.57e-06	2.19e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PLA2G4A—breast cancer	2.55e-06	2.17e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NCOR1—breast cancer	2.55e-06	2.17e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTM1—breast cancer	2.55e-06	2.17e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HPGDS—breast cancer	2.54e-06	2.17e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HBA1—breast cancer	2.52e-06	2.15e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CA—breast cancer	2.49e-06	2.12e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ACHE—breast cancer	2.46e-06	2.1e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTT1—breast cancer	2.46e-06	2.1e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GPX1—breast cancer	2.44e-06	2.08e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP1A1—breast cancer	2.41e-06	2.06e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—breast cancer	2.4e-06	2.05e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ERCC2—breast cancer	2.39e-06	2.04e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CAV1—breast cancer	2.37e-06	2.02e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP17A1—breast cancer	2.33e-06	1.99e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ENO1—breast cancer	2.31e-06	1.97e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS1—breast cancer	2.31e-06	1.97e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HRAS—breast cancer	2.3e-06	1.96e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.26e-06	1.93e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP2D6—breast cancer	2.26e-06	1.93e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MTHFR—breast cancer	2.25e-06	1.92e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NCOA2—breast cancer	2.22e-06	1.89e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CG—breast cancer	2.16e-06	1.84e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—FASN—breast cancer	2.15e-06	1.84e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—BCHE—breast cancer	2.15e-06	1.83e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC5A5—breast cancer	2.12e-06	1.81e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CAV1—breast cancer	2.08e-06	1.77e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NQO1—breast cancer	2.05e-06	1.75e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC2A1—breast cancer	2.05e-06	1.75e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT1—breast cancer	2.03e-06	1.73e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP1B1—breast cancer	1.96e-06	1.67e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CA—breast cancer	1.92e-06	1.64e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HSP90AA1—breast cancer	1.92e-06	1.64e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CD—breast cancer	1.9e-06	1.62e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CG—breast cancer	1.89e-06	1.61e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NCOA1—breast cancer	1.87e-06	1.6e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—STK11—breast cancer	1.84e-06	1.57e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP19A1—breast cancer	1.84e-06	1.57e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NOS3—breast cancer	1.79e-06	1.53e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—COMT—breast cancer	1.72e-06	1.46e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTP1—breast cancer	1.71e-06	1.46e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HMOX1—breast cancer	1.68e-06	1.44e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ITPR1—breast cancer	1.68e-06	1.43e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CD—breast cancer	1.66e-06	1.42e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CB—breast cancer	1.65e-06	1.41e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALB—breast cancer	1.64e-06	1.4e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS2—breast cancer	1.64e-06	1.4e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCB1—breast cancer	1.62e-06	1.38e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TYMS—breast cancer	1.59e-06	1.35e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AKT1—breast cancer	1.57e-06	1.34e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NOS3—breast cancer	1.57e-06	1.34e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NCOR1—breast cancer	1.57e-06	1.34e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTM1—breast cancer	1.57e-06	1.34e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.57e-06	1.34e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPX1—breast cancer	1.5e-06	1.28e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP1A1—breast cancer	1.49e-06	1.27e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ERCC2—breast cancer	1.47e-06	1.26e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CB—breast cancer	1.45e-06	1.24e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS2—breast cancer	1.44e-06	1.22e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTEN—breast cancer	1.43e-06	1.22e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MTHFR—breast cancer	1.39e-06	1.18e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CAV1—breast cancer	1.28e-06	1.09e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTEN—breast cancer	1.25e-06	1.07e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CG—breast cancer	1.16e-06	9.93e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CD—breast cancer	1.02e-06	8.73e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALB—breast cancer	1.01e-06	8.62e-06	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CA—breast cancer	1.01e-06	8.6e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NOS3—breast cancer	9.67e-07	8.25e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CB—breast cancer	8.92e-07	7.61e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS2—breast cancer	8.84e-07	7.54e-06	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CA—breast cancer	8.83e-07	7.53e-06	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AKT1—breast cancer	8.23e-07	7.02e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTEN—breast cancer	7.71e-07	6.58e-06	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AKT1—breast cancer	7.21e-07	6.15e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CA—breast cancer	5.44e-07	4.64e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AKT1—breast cancer	4.44e-07	3.79e-06	CbGpPWpGaD
